FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to methods for producing a population of cells highly sensitive to Clostridial neurotoxin, as well as determining the activity of the modified or recombinant neurotoxin and identifying the composition of the Clostridial neurotoxin for therapeutic and/or cosmetic use.
EFFECT: invention enables to obtain cell populations having high sensitivity to clostridial neurotoxins for use in analyses.
54 cl, 14 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| NEW METHODS OF USING BOTULINUM NEUROTOXIN FOR TREATING TREMOR | 2020 |
|
RU2826569C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS SPECIFICALLY BINDING TO BOTULINUM NEUROTOXIN TYPE A, AND METHOD OF USING THEM FOR THERAPY OR EMERGENCY PREVENTION OF INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2766348C1 |
